Treatment of lung cancer

SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Azacitidine, Research, Safety, Doctor of Science, GPS, SLS, Treatment of lung cancer, ODD, Food and Drug Administration, Clinical trial, Administration, Patient, CDK9, FDA, Pembrolizumab, Ovarian cancer, MD, Development, Death, Survival, IDMC, Lymphoma, Financial toxicity, Bone marrow, AML, Fast Track, PTCL, Venetoclax, Pharmaceutical industry

Phase 1/2 Study in combination with pembrolizumab (Keytruda®) in ovarian cancer:

Key Points: 
  • Phase 1/2 Study in combination with pembrolizumab (Keytruda®) in ovarian cancer:
    Final data were presented in November 2023 at the International Gynecologic Cancer Society Annual 2023 Annual Global Meeting.
  • Financial Results for the Third Quarter 2023:
    Research and Development Expenses: Research and development expenses for the third quarter of 2023 were $5.8 million, compared to $4.3 million for the same period in 2022.
  • Acquired In-Process Research and Development: There was no acquired in-process research and development in the third quarter of 2023 or the third quarter of 2022.
  • Cash Position: As of September 30, 2023, cash and cash equivalents totaled approximately $4.0 million.

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Retrieved on: 
Friday, November 17, 2023
Science, Biotechnology, Research, Oncology, Health, Data Management, Technology, Genetics, TMB, GCN, Multimedia, Whole genome sequencing, Personalized medicine, Conference, Treatment of lung cancer, Diagnosis, MET, Insight, NGS, Biomarker, Poster, AACR, NSCLC, Antibiotics, Cancer, Hong Kong

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Key Points: 
  • Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.
  • (Photo: Business Wire)
    Genome Insight's presentation will feature the outcomes of a collaborative real-world evidence program on TE-WGS in lung cancers.
  • Genome Insight will present the case of a 78-year-old Asian man from Hong Kong with poorly differentiated Non-Small Cell Lung Cancer (NSCLC).
  • "We are thrilled to present this real-world evidence from Hong Kong at the esteemed 2023 AACR-KCA Joint Conference," said Ryul Kim, Chief Technology Officer.

A Type of Allergy Medicine Might Help Treat Lung Cancer, Research Suggests

Retrieved on: 
Wednesday, December 6, 2023
DOI, Nature, Marc, Allergy, Cancer research, Patient, Lung cancer, National Institutes of Health, TARGET, Cancer, Doctor of Philosophy, Bangladesh Technical Education Board, Cancer Research Institute, Bristol Myers Squibb, Dermatitis, Immunology, Biomarker, Columbia University, Bone marrow, Immunity, Artificial intelligence, MTR, Austrian Academy of Sciences, CRI, Asthma, AACR, FAAD, Hope, Clinical trial, Mouse, Agency, Immunotherapy, Treatment of lung cancer, Human, SingHealth, Neoplasm, NSCLC, Vaccine, Pharmaceutical industry, Science, Chin, Research, MD

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

Key Points: 
  • Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • "Strikingly, we found that IL-4 blockade enhanced lung cancer response to checkpoint blockade in mice and in six lung cancer patients with treatment-resistant disease.
  • "In our relentless pursuit of progress, the Cancer Research Institute (CRI) proudly supports the visionary team at the Icahn School of Medicine at Mount Sinai.

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Research and development, American College, IND, MGD, PD, Public expenditure, Investigational New Drug, G&A, Inflammation, Treatment of lung cancer, MYC, R, GSPT1, Neoplasm, CDK2, Drug discovery, DSM-IV codes, Autoimmune disease, American College of Rheumatology, Roche, Cancer, Autoimmunity, Finance, Therapy, Patient, ACR, Administration, CIA, VAV1, Pharmaceutical industry, Vaccine, Cryptocurrency

"This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • "This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $28.3 million, compared to $21.3 million for the third quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $8.7 million compared to $7.0 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.

LUNGevity Foundation Announces $1.2M in Lung Cancer Workforce Development Research Awards

Retrieved on: 
Wednesday, November 1, 2023
Neoplasm, Radiation, Faculty, Research, NSCLC, Health equity, RNA, ICI, Doctor of Philosophy, Cell, METTL3, Disease, Partnership, Radiation therapy, SCLC, MPH, LCI, Health, Lung cancer, Physician, Workforce, Veteran, Maintenance, Immune system, KIR, Breast cancer, Immunotherapy, Checkpoint, Cancer, Patient, Laboratory, ICIS, Durham, MD, Growth, Development, American Society for Radiation Oncology, LSD1, ASTRO, Survival, FDA, MBA, Treatment of lung cancer, Society, Death, Genomics, Risk, Carcinoma, Diagnosis, LCS, Nursing, Medical imaging, Vaccine

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to continue its multifaceted investment in the thoracic oncology workforce by announcing the recipients of four awards — the Career Development Award, the VA Research Scholar Award, the Health Equity and Inclusiveness Research Fellow Award, and the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant. 

Key Points: 
  • "Progress in lung cancer research is only possible with a vibrant and diverse thoracic oncology workforce," notes Upal Basu Roy, PhD, MPH, executive director, LUNGevity Research.
  • LUNGevity Foundation is honored to partner with the Lung Cancer Initiative (LCI) to co-fund Dr. LoPiccolo's project on the genomics of young-onset lung cancer.
  • The Lung Cancer Initiative is a leading nonprofit in North Carolina that connects the lung cancer community with the research and medical community.
  • LUNGevity's 2023 VA Research Scholar Award recipient is:
    Lung cancer screening (LCS) provides an important opportunity to find lung cancer early when it is the most treatable.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Survival, Neoplasm, FDA, Pemetrexed, PD-L1, McGill University Health Centre, SCLC, NSCLC, Aes, NYSE, ESMO, Food, Trae tha Truth, Lung cancer, Cisplatin, American Joint Committee on Cancer, Congress, Head, MRK, European Society for Medical Oncology, PCR, Carcinoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Treatment of lung cancer, Research, Neoadjuvant therapy, Disease, Merck & Co., Risk, MPR, EFS, RECIST, Safety, AJCC, Cancer, European Society of Gynaecological Oncology, Patient, OS, Death, Associate, Pharmaceutical industry, Merck

The 36-month OS rates were 71.3% for patients who received the KEYTRUDA-based regimen versus 64.0% for patients who received the chemotherapy-placebo regimen.

Key Points: 
  • The 36-month OS rates were 71.3% for patients who received the KEYTRUDA-based regimen versus 64.0% for patients who received the chemotherapy-placebo regimen.
  • The 36-month EFS rates were 54.3% for patients who received the KEYTRUDA-based regimen versus 35.4% for patients who received the chemotherapy-placebo regimen.
  • “The results of KEYNOTE-671 represent an important milestone in our fight to improve treatment outcomes for patients with surgically resectable non-small cell lung cancer.
  • “Non-small cell lung cancer is the leading cause of cancer-related death worldwide and this new regimen applies to a wide range of surgically resectable patients.

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

Retrieved on: 
Tuesday, October 17, 2023
Cancer, Glomus tumor, Telephone, Hypocalcemia, Treatment of lung cancer, NSCLC, Trial of the century, First grade, Aes, SCLC, Cytokine release syndrome, Safety, Interim, Conference call, MD Anderson Cancer Center, Associate professor, Therapy, SD, DLT, University, Webcast, MGD, CRS, Lung, PD, Principal investigator, Neoplasm, Optimism, Prostate, Hypotension, Conference, Patient, MYC, Vaccine, Pharmaceutical industry, Medical imaging, GSPT1

BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including lung cancers and high-grade neuroendocrine cancer. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered by Monte Rosa Therapeutics. Cancers driven by MYC overexpression have been demonstrated to be dependent on GSPT1, creating a therapeutic opportunity.

Key Points: 
  • MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered by Monte Rosa Therapeutics.
  • Interim clinical data from the MRT-2359 study have demonstrated favorable tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in heavily pre-treated patients with lung cancers and high-grade neuroendocrine cancer.
  • Monte Rosa is continuing with dose level and schedule optimization in this ongoing study.
  • We continue to explore optimal doses and dosing schedules as we collect clinical data from this ongoing Phase 1/2 study," said Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa Therapeutics.

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
Toxicity, Carcinoma, AACR, Diabetes, Clinical trial, Cancer, Pulmonary toxicity, TUSC2, Research, NSCLC, Treatment of lung cancer, Lung cancer, Hynes Convention Center station, Fast track (FDA), SCLC, Patient, Hynes Convention Center, Therapy, Conference, Disease, Pharmaceutical industry

AUSTIN, Texas, Oct. 4, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that research collaborators will present positive clinical and preclinical data from studies of its lead product candidate, REQORSA® (quaratusugene ozeplasmid) used for the treatment of lung cancers, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place from October 11-15, 2023 at the Hynes Convention Center in Boston. REQORSA is a non-viral gene therapy that leads to expression of the TUSC2 tumor suppressor gene in cancers.

Key Points: 
  • REQORSA is a non-viral gene therapy that leads to expression of the TUSC2 tumor suppressor gene in cancers.
  • "The encouraging Phase 1 results in the Acclaim-1 trial document REQORSA's favorable safety profile thus far and show early efficacy in patients with non-small cell lung cancer (NSCLC) whose disease has progressed on Tagrisso.
  • "In addition, the preclinical data presented by our research collaborators is very encouraging, as we know that despite the broader success of immunotherapies, such as checkpoint inhibitors, they have limited efficacy in the treatment of small cell lung cancer.
  • Details of the presentations are outlined below:
    "Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and osimertinib"

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.